Phase II Study Incorporating Pegylated Interferon in the Treatment for Children with High-Risk Melanoma
Latest Information Update: 03 Jul 2026
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Temozolomide (Primary) ; Interferon alpha-2b; Peginterferon
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 25 Jun 2026 Planned End Date changed from 1 May 2026 to 1 May 2031.
- 05 Jul 2023 Planned End Date changed from 1 May 2023 to 1 May 2026.
- 30 Mar 2020 Planned End Date changed from 1 Sep 2018 to 1 May 2023.